---
title: High-Risk Breast Cancer Management
markmap:
  initialExpandLevel: 3
  maxWidth: 200
  colorFreezeLevel: 6
---
- Breast
  - HIGH RISK For Breast Cancer
    - No Germline mutation
      - IBIS Residual Lifetime Risk >=20% and 10-year >= 5%
        - [x] Annual MMG and MRI (Minimum age 30 and 25 respectively)
        - [x] Chemoprevention with AI or Tamoxifen (20mg vs babytam)
      - IBIS Residual Lifetime Risk >=20% and 10-year < 5%
        - [x] Annual MMG and MRI (Minimum age 30 and 25 respectively)
    - Germline mutation
      - Management per mutation

  - Noninvasive Breast Event
    - LCIS or ADH
      - [x] Chemoprevention with AI or Tamoxifen (20mg vs babytam) IRRESPECTIVE of ER status 
    - DCIS
      - ER+ve
        - [x] Mastectomy VERSUS BCS → RT → ET
        - [x] Adjuvant ET for contralat. chemoPPX. ET should be TAM (Pre) vs AI (Post) vs Tam 5mg PO qD x 3yr
        - [x] Oncotype DCIS or DecisionRT post BCS can omit RT if low score
      - ER-ve
        - [x] Mastectomy VERSUS BCS → RT

  - EARLY BREAST CANCER (I, II, III)
    - PREMENOPAUSAL HR POSITIVE HER2 NEGATIVE
      - pT1a N0
        - [x] Definitive Surgery. [Role of ET?]
      - pT1b-2 N0
        - [x] Definitive Surgery → RS (ddAC/TC) → Adjuvant ET [TAM (pre) or AI (post)] x 5 years +/- 5 years (BCI)
      - pT1-2 N1
        - [x] [Consider NACT] Definitive Surgery → RS (ddAC/TC) → Adjuvant ET (Ov Suppression if pre) x 5 years +/- 5 years (BCI)
      - pT3-4 N0
        - [x] [Consider NACT] Definitive Surgery → TC OR ddAC/T [RS NOT validated] → Adjuvant ET x 5 years +/- 5 years (BCI).
      - pT3 N1-3
        - [x] [Consider NACT] Definitive Surgery → ddAC/T [RS NOT validated] → Adjuvant ET (Ov Suppression if pre) x 5 years + 5 years. 
      - Based off TAILORx (Node NEG. 2018) RxPONDER (1 to 3 nodes. 2021)
        - N+ve
          - [x] → Chemotherapy irrespective of RS
        - N-ve
          - [x] RS ≥26: Chemo. 
          - [x] RS 16-25 : Discuss.
          - [x] ≤15 or less → no chemo
      - Adjuvant Targeted therapies
        - [x] OLAPARIB in high-risk ER+ HER2- gBRCA1/2 Stage II and III
        - [x] ABEMACICLIB in high risk patient: pN2/3 OR pN1 with either T3 OR Grade III
    - POSTMENOPAUSAL HR POSITIVE HER2 NEGATIVE
      - pT1a N0
        - [x] Definitive Surgery. [Role of ET?]
      - pT1b-2 N0
        - [x] Definitive Surgery → RS (ddAC/TC) → Adjuvant ET [TAM (pre) or AI (post)] x 5 years +/- 5 years (BCI)
      - pT1-2 N1
        - [x] [Consider NACT] Definitive Surgery → RS (ddAC/TC) → Adjuvant ET (Ov Suppression if pre) x 5 years +/- 5 years (BCI)
      - pT3-4 N0
        - [x] [Consider NACT] Definitive Surgery → TC OR ddAC/T [RS NOT validated] → Adjuvant ET x 5 years +/- 5 years (BCI).
      - pT3 N1-3
        - [x] [Consider NACT] Definitive Surgery → ddAC/T [RS NOT validated] → Adjuvant ET (Ov Suppression if pre) x 5 years + 5 years. 
      - Based off TAILORx (Node NEG. 2018) RxPONDER (1 to 3 nodes. 2021)
        - Postmenopausal (Node + or -)
          - [x] → RS ≥26: benefited from Chemo regardless of LNs
      - Adjuvant Targeted therapies
        - [x] OLAPARIB in high-risk ER+ HER2- gBRCA1/2 Stage II and III
        - [x] ABEMACICLIB in high risk patient: pN2/3 OR pN1 with either T3 OR Grade III
    - HR NEGATIVE HER2 POSITIVE
      - cT1a N0
        - [x] Definitive Surgery (Role of Adj Anti HER2?)
      - cT1b-1c N0
        - [x] Definitive Surgery → Weekly Txl/Herceptin (APT) vs H alone (age 75+)
      - cT12-4 OR N1-3
        - [x] Txr/Carbo/Herceptin/Perjeta NACT vs. TDM1/Perjeta → Definitive Surgery
        - No pCR
          - [x] TDM-1 to complete a year
        - pCR
          - [x] HP to complete a year
    - HR POSITIVE HER2 POSITIVE
      - cT1a N0
        - [x] Definitive Surgery (Role of Adj Anti HER2?)
      - cT1b-1c N0
        - [x] Definitive Surgery → Weekly Txl/Herceptin (APT) vs H alone (age 75+) + TAM/AI/OFS+AI
      - cT2-4 OR N1-3
        - [x] Txr/Carbo/Herceptin/Perjeta NACT vs. TDM1/Perjeta → Definitive Surgery
        - No pCR
          - [x] TDM-1 to complete a year + TAM/AI/OFS+AI 
        - pCR
          - [x] HP to complete a year + TAM/AI/OFS+AI → Neratinib + TAM/AI/OFS+AI
    - HR NEGATIVE HER2 NEGATIVE
      - cT1a N0
        - [x] Definitive Surgery (Role of Adj Chemotherapy?)
      - cT1b-3 N1-3
        - [x] NACT Carbo/Txl/Pembro → ddAC / Pembro → Definitive Surgery
        - No pCR
          - [x] Adj. Pembro then Capecitabine (Standard 1250mg/m2 vs Metronomic 600mg/m2)
        - pCR
          - [x] Adj. Pembro then Metronomic Cape. PARPi if HBOC (if very high risk)
        - [x] PARPi if HBOC

  - METASTATIC BREAST CANCER (IV)
    - PREMENOPAUSAL HR POSITIVE HER2 NEGATIVE
      - 1st line
        - [x] OFS+AI+CDK4/6 (Kisqali per MONALEESA-7)
      - 2nd line
        - Soft progression
          - [x] → OFS / Faslo / Abema
        - PIK3CA mut
          - [x] → OFS / Faslo / Piqray
        - ESR1 mut
          - [x] → OFS / Elacestrant
        - HBOC/sBRCA/gPALB2
          - [x] → PARPi
        - Otherwise
          - [x] OFS / Faslodex/Everolimus vs Enhertu (IHC 1+ or 2+ with Gp5)
      - 3rd line
        - [x] Enhertu (IHC 1+ or 2+ with Gp5) OR Chemotherapy
      - Further lines
        - [x] CHEMOTHERAPY
    - POSTMENOPAUSAL HR POSITIVE HER2 NEGATIVE
      - 1st line
        - [x] AI+CDK4/6. Consider holding CDK if low volume.
      - 2nd line
        - Soft progression
          - [x] → Faslo / Abema
        - PIK3CA mut
          - [x] → Faslo / Piqray
        - ESR1 mut
          - [x] → Elacestrant
        - HBOC/sBRCA/gPALB2
          - [x] → PARPi
        - Otherwise
          - [x]
          - [x] Faslodex/Everolimus
      - 3rd line
        - [x] Enhertu (IHC 1+ or 2+ with Gp5) OR Chemotherapy
      - Further lines
        - [x] CHEMOTHERAPY

    - HR NEGATIVE HER2 POSITIVE
      - 1st line
        - [x] Taxane/HP (vs Tr/HP) → maintenance HP
      - 2nd line
        - [x] Enhertu vs Cape/Tucatinib/Herceptin
      - 3rd line
        - [x] Enhertu vs Cape/Tucatinib/Herceptin vs Margetuximab vs Cape/Neratinib
      - Further lines
        - [x] CHEMOTHERAPY

    - HR POSITIVE HER2 POSITIVE
      - 1st line
        - [x] Taxane / HP (vs Tr/HP) → maintenance HP + ET (OFS/AI vs AI)
      - 2nd line
        - [x] Enhertu vs Cape/Tucatinib/Herceptin vs Faslo / Abema / H
      - 3rd line
        - [x] Enhertu vs Cape/Tucatinib/Herceptin vs Margetuximab vs Cape/Neratinib
      - Further lines
        - [x] CHEMOTHERAPY

    - HR NEGATIVE HER2 NEGATIVE
      - 1st line
        - [x] Pembro (22C3 +ve) +/- Taxol/Abraxane/CarboGem
        - [x] Olaparib/Talzaporib (germline BRCA1/BRCA2 OR per TBCRC 048 gPALB2 OR somatic BRCA2)
        - [x] If not NGS, Paclitaxel (3 on 1 off)
        - [x] Capecitabine (Std vs low dose)
        - [x] Taxotere/Cytoxan
      - 2nd line
        - [x] Trodelvy
        - [x] Enhertu (IHC 1+ or 2+ with Gp5)
        - [x] CHEMOTHERAPY
        - [x] Consider Ixabepilone if progression on Adria and Taxane
      - 3rd line
        - [x] Trodelvy
        - [x] Enhertu (IHC 1+ or 2+ with Gp5)
        - [x] CHEMOTHERAPY
        - [x] Consider Halaven if progression on two prior chemotherapy agents
      - Further lines
        - [x] CHEMOTHERAPY

  - LOCAL/REGIONAL RECURRENCE
    - ER POSITIVE: CALOR demonstrated no benefit in re-administration of Chemotherapy
    - ER NEGATIVE: Modest benefit of rechallenge with chemotherapy

  - SPECIFIC SITUATIONS
    - Encapsulated Papillary → managed as DCIS
    - Tubular, Mucinous and Papillary → Adj Endocrine Rx. Add Chemo if pN1a-3
    - Adenoid Cystic TNBC is associated with favorable prognosis and might not need chemotherapy unless N+ disease
    - Male BC → 
      - ER+ 
        - [x] Definitive Surgery → TAM (NOT AI alone) Can use AI with GnRH
      - ER-ve 
        - [x] Definitive Surgery → Chemotherapy (ddAC/T)
      - Advanced ER+
        - [x] CDK4/6 + either TAM OR AI/GnRH agonist → Faslodex as 2nd line
    - Capecitabine
      - [x] STANDARD 1250mg/m2 D1-14 of 21D CYCLE * 8 CYCLES. METRONOMIC 650mg/m2 D1-28 of 28D CYCLE *12 CYCLES
    - NACT Carbo/Txl/Pembro might require Neupogen support per weekly basis
    - Per early HERA trials
      - [x] EF drop is LVEF ≤ 16% drop from baseline OR ≤ 40%. TTE q3Months while on HP
    - HP and TDM1 are given to complete 1 full year of AntiHER2 therapy
    - Per EBCTG
      - [x] ER3+ 10% to 100% all derive benefit
      - [x] ER- PR+ derive no benefit
    - Adriamycin is recommended in N2/N3 ER+ OR TNBC
    - Can Skip RT If >65 ER+ pN0 s/p Mastectomy
    - Need postop RT if pT3 or pN+
